Kimberly Y. Smith, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Community-associated methicillin-resistant Staphylococcus aureus colonization in high-risk groups of HIV-infected patients.
   Popovich KJ, Smith KY, Khawcharoenporn T, Thurlow CJ, Lough J, Thomas G, Aroutcheva A, Zawitz C, Beavis KG, Weinstein RA, Hota B.
   Clin Infect Dis. 2012
   2012 May
   54(9):1296-303. doi: 10.1093/cid/cis030. Epub 2012 Feb 21.
   
2. Treating women with HIV: is it different than treating men?
   Aziz M, Smith KY.
   Curr HIV/AIDS Rep. 2012
   2012 Jun
   9(2):171-8. doi: 10.1007/s11904-012-0116-x.
   
3. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.
   Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K.
   J Natl Med Assoc. 2012
   2012 Jul-Aug
   104(7-8):366-76.
   
4. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic.
   Khawcharoenporn T, Kendrick S, Smith K.
   AIDS Patient Care STDS. 2012
   2012 Apr
   26(4):222-33. doi: 10.1089/apc.2011.0202. Epub 2012 Mar 9.
   
5. Challenges and successes in linking HIV-infected women to care in the United States
   Aziz M, Smith KY
   Clin Infect Dis
   2011 Jan 15
   52 Suppl 2:S231-7
   
6. Classic pyomyositis of the extremities as an unusual manifestation of Blastomyces dermatitidis: a report of two cases
   Lin MY, Chihara S, Smith KY, Kessler HA, Sha BE, Proia LA
   Mycoses
   2010 Jul
   53(4):356-9
   
7. Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174
   Smith K, Zheng L, Bosch R, Margolis DM, Tenorio A, Napolitano L, Saag M, Connick E, Gross B, Francis I, Valdez H, Muurahainen N, Stocker V, Pollard R
   AIDS Res Hum Retroviruses
   2010 Apr
   26(4):425-32
   
8. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
   Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY
   AIDS Res Hum Retroviruses
   2010 Apr
   26(4):407-17
   
9. Paying the price for late starts and early stops: racial and sex disparities in HIV-related mortality
   Smith KY
   Clin Infect Dis
   2009 Nov 15
   49(10):1579-81
   
10. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team
    AIDS
    2009 Jul 31
    23(12):1547-56
    
11. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
    Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; ALERT (COL103952) Study Team
    AIDS Res Ther
    2008 Mar 28
    5:5